Hui-Hsin Ko1,2, Shih-Lung Cheng3,4, Jang-Jaer Lee5,2, Hsin-Ming Chen1,5,2,6, Mark Yen-Ping Kuo1,5,2, Shih-Jung Cheng1,5,2. 1. Graduate Institute of Clinical Dentistry, School of Dentistry, National Taiwan University, Taipei, Taiwan. 2. Department of Dentistry, National Taiwan University Hospital, College of Medicine, Taipei, Taiwan. 3. Department of Internal Medicine, Far Eastern Memorial Hospital, Taipei, Taiwan. 4. Department of Chemical Engineering and Materials Science, Yuan-Ze University, Chung-Li, Taiwan. 5. School of Dentistry, National Taiwan University, Taipei, Taiwan. 6. Graduate Institute of Oral Biology, School of Dentistry, National Taiwan University, Taipei, Taiwan.
Abstract
BACKGROUND: Aldo-keto reductase family 1 member B10 (AKR1B10) is implicated in xenobiotic detoxification and has disparate functions in tumorigenesis that are dependent on the cell types. The purpose of this study was to investigate the clinicopathological significance of AKR1B10 as a prognostic marker for oral squamous cell carcinomas (OSCCs). METHODS: AKR1B10 protein expression was analyzed by immunohistochemistry in 77 patients with OSCC. RESULTS: The AKR1B10 labeling score for OSCCs (1.16 ± 1.14) was significantly higher than that for normal oral mucosa (0.10 ± 0.23; p < .0001). High expression of AKR1B10 significantly correlated with large tumor size (p = .041), advanced TNM classification (p = .037), and patient's areca quid chewing habit (p = .025). Multivariate analysis revealed that high AKR1B10 labeling score >1.16 (hazard ratio, 3.647; p = .001) significantly correlated with mortality. CONCLUSION: AKR1B10 overexpression is an independent poor prognostic biomarker for OSCC. AKR1B10 inhibitors may be promising in clinical trials against OSCC.
BACKGROUND:Aldo-keto reductase family 1 member B10 (AKR1B10) is implicated in xenobiotic detoxification and has disparate functions in tumorigenesis that are dependent on the cell types. The purpose of this study was to investigate the clinicopathological significance of AKR1B10 as a prognostic marker for oral squamous cell carcinomas (OSCCs). METHODS:AKR1B10 protein expression was analyzed by immunohistochemistry in 77 patients with OSCC. RESULTS: The AKR1B10 labeling score for OSCCs (1.16 ± 1.14) was significantly higher than that for normal oral mucosa (0.10 ± 0.23; p < .0001). High expression of AKR1B10 significantly correlated with large tumor size (p = .041), advanced TNM classification (p = .037), and patient's areca quid chewing habit (p = .025). Multivariate analysis revealed that high AKR1B10 labeling score >1.16 (hazard ratio, 3.647; p = .001) significantly correlated with mortality. CONCLUSION:AKR1B10 overexpression is an independent poor prognostic biomarker for OSCC. AKR1B10 inhibitors may be promising in clinical trials against OSCC.
Authors: Elizabeth Mazzio; Ramesh Badisa; Nzinga Mack; Shamir Cassim; Masa Zdralevic; Jacques Pouyssegur; Karam F A Soliman Journal: Cancer Genomics Proteomics Date: 2020 Sep-Oct Impact factor: 4.069